Ascletis Pharma Inc Working Capital to Net Assets Ratio
Ascletis Pharma Inc working capital to net assets ratio. Ascletis Pharma Inc (2VJ) has a Working Capital to Net Assets ratio of 92.7% as of December 2025. Working capital of €1.79 Billion (current assets of €1.92 Billion minus current liabilities of €127.59 Million) is measured against net assets of €1.93 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Ascletis Pharma Inc (2VJ) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Ascletis Pharma Inc (2016–2025)
Working capital to net assets ratio of Ascletis Pharma Inc from 2016 to 2025. This chart shows how Ascletis Pharma Inc's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the ratio stands at 92.7%, reflecting working capital of €1.79 Billion against net assets of €1.93 Billion EUR. See defensive interval ratio of Ascletis Pharma Inc to measure how many days the company can operate on defensive assets alone.
Ascletis Pharma Inc Working Capital to Net Assets Ratio by Year (2016–2025)
Ascletis Pharma Inc working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Ascletis Pharma Inc from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Ascletis Pharma Inc's balance sheet.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 92.7% | €1.79 Billion | €1.93 Billion | €1.92 Billion | €127.59 Million | ▲ +0.3 pp |
| 2024 | 92.5% | €1.82 Billion | €1.97 Billion | €1.97 Billion | €153.05 Million | ▼ -1.1 pp |
| 2023 | 93.6% | €2.19 Billion | €2.34 Billion | €2.33 Billion | €140.68 Million | ▼ -2.3 pp |
| 2022 | 95.9% | €2.44 Billion | €2.54 Billion | €2.54 Billion | €108.19 Million | ▲ +2.8 pp |
| 2021 | 93.1% | €2.54 Billion | €2.73 Billion | €2.63 Billion | €90.97 Million | ▲ +0.7 pp |
| 2020 | 92.4% | €2.76 Billion | €2.98 Billion | €2.83 Billion | €73.77 Million | ▼ -1.0 pp |
| 2019 | 93.4% | €3.10 Billion | €3.32 Billion | €3.19 Billion | €87.65 Million | ▼ -2.0 pp |
| 2018 | 95.4% | €3.27 Billion | €3.43 Billion | €3.36 Billion | €93.41 Million | ▲ +6.1 pp |
| 2017 | 89.3% | €776.39 Million | €869.83 Million | €875.62 Million | €99.23 Million | ▼ -6.7 pp |
| 2016 | 96.0% | €392.61 Million | €409.08 Million | €466.01 Million | €73.40 Million | — |